Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 1;23(4):218-223.
doi: 10.1097/HPC.0000000000000364. Epub 2024 May 17.

TNF alpha Inhibitors in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis

Asma Mahmood  1 , Mahnoor Farooq Raja  1 , Habiba Imran  2 , Bushra Zahoor  1 , Mohammad Sadiq Khan Khakwani  3 , Nikhil Duseja  4 , Ihtisham Rahman  5 , Aiman Murtaza  6 , Hafiz Muhammad Faizan Abid  7 , Muhammad Sohail Sattar  8 , Neha Bajaj  9 , Saneha Bajaj  10 , Laiqa Tariq  3 , Aimen Shafiq  7
Affiliations
Meta-Analysis

TNF alpha Inhibitors in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis

Asma Mahmood et al. Crit Pathw Cardiol. .

Abstract

Background: Recent studies have focused on treating cardiac sarcoidosis (CS) with corticosteroids primarily mitigating symptoms and reducing the risk of mortality and other cardiovascular complications. A promising new treatment approach involves tumor necrosis factor (TNF) alpha inhibitors.

Methodology: A systematic search was conducted on PubMed, the Cochrane Library, and Elsevier's Science Direct databases to identify studies comparing TNF alpha inhibitors with other drugs in CS patients who had heart failure. The analyses were conducted using the random-effects model.

Results: The study's primary outcome is an increase in ejection fraction (EF), secondary outcomes include a reduction in the dose of prednisone at 6 and 12 months, maximum standardized uptake value by cardiac tissue, and fluorodeoxyglucose uptake by cardiac myocytes on positron emission tomography scan. The total number of pooled participants was 154 out of which 140 met the Heart Rhythm Society criteria for CS. The pooled analysis showed that treatment with the TNF alpha inhibitors was associated with a significant increase in EF [weighted mean difference (WMD), 46.272; 95% confidence interval (CI), 40.60-51.94, P < 0.001; I2, 75.74%], reduction in the dose of prednisone at 6 months (WMD, 9.20; 95% CI, 7.65-10.75; P < 0.001; I2, 13.33%) and at 12 months (WMD, 6.40; 95% CI, 4.74-8.07; P < 0.001; I2, 9.37%); decrease in myocardial maximum standardized uptake value (WMD, 1.99; 95% CI, 0.91-3.06; P < 0.001; I2: 97%) and reduction in fluorodeoxyglucose uptake by cardiac myocytes (WMD, 1.55; 95% CI, 1.09-2.00; P < 0.001; I2, 32.29) on positron emission tomography scans.

Conclusions: The research findings suggest that TNF alpha inhibitors improve EF, reduce required steroid dosage, and improve clinical outcomes. Nonetheless, further high-quality randomized controlled trials with large sample sizes are needed to assess other impacts of this therapy on patients with CS.

PubMed Disclaimer

References

    1. Chaudhary R, Rajaratnam A, Harinstein ME. Tumor necrosis factor-α inhibitors in cardiac sarcoidosis management: evaluating therapeutic efficacy and future directions. Am J Cardiol. 2023;205:493–494.
    1. Birnie DH. Cardiac sarcoidosis. Semin Respir Crit Care Med. 2020;41:626–640.
    1. Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. J Card Fail. 2021;27:83–91.
    1. Kobak S. Treat to target and tight control: could be a new approach in the treatment of sarcoidosis?. Intractable Rare Dis Res. 2023;12:22–28.
    1. Churchill R, Sykora D, Castrichini M, et al. Clinical response to tumor necrosis factor-α inhibitor therapy in the management of cardiac sarcoidosis. Am J Cardiol. 2023;205:20–27.

MeSH terms

LinkOut - more resources